Haleon (HLN) Net Debt Issuances and Repayments (2022 - 2023)

Haleon (HLN) posted Net Debt Issuances and Repayments of -$13.1 billion for Q2 2023, down 11.95% on a QoQ basis from -$11.7 billion in Q4 2022.

Haleon (HLN) Net Debt Issuances and Repayments (2022 - 2023) Analysis & Trends

Haleon's Net Debt Issuances and Repayments history runs 2 years deep, the most recent figure standing at -$13.1 billion for Q2 2023.

Quarterly Net Debt Issuances and Repayments changed N/A year-over-year to -$13.1 billion in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$13.1 billion (changed N/A YoY) and the FY2022 annual result came in at -$12.4 billion, changed N/A from the prior year.
Net Debt Issuances and Repayments was -$13.1 billion for Q2 2023 at Haleon, down from -$11.7 billion in the prior quarter.
Across five years, Net Debt Issuances and Repayments topped out at -$11.7 billion in Q4 2022 and bottomed at -$13.1 billion in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Debt Issuance (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Vireo Growth	10.57 Bn	10.41 Bn	59.30 Mn	-

Download Data